Early-onset Obesity and Cognitive Impairment in Children With Pseudohypoparathyroidism
Learn more about:
Related Clinical Trial
Disorders of Bone and Mineral Metabolism
QoL and Cognitive Function in Patients With Hypoparathyroidism
Theophylline Treatment for Pseudohypoparathyroidism – Children 2-12 Years Old
Study of the Regulation of Parathyroid Hormone Secretion in Pseudohypoparathyroidism
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
Hypoparathyroidism in Denmark
Physiologic Regulation of FGF-23
Theophylline for Treatment of Pseudohypoparathyroidism
Characterization of Patients With Non-surgical Hypoparathyroidism and Pseudohypoparathyroidism
Theophylline as a Treatment for Children With Pseudohypoparathyroidism Type 1a (Albright Hereditary Osteodystrophy)
Evaluation of rhGH Replacement Therapy in Patients With Pseudohypoparathyroidism Type Ia (PHP Ia)
Theophylline Treatment for Pseudohypoparathyroidism
Early-onset Obesity and Cognitive Impairment in Children With Pseudohypoparathyroidism
Energy Expenditure and Body Composition in Pseudohypoparathyroidism 1a
Glucose Homeostasis in Pseudohypoparathyroidism